Insight

New Paper Alert: Perioperative Chemoimmunotherapy In Resectable Stage II–IIIA NSCLC – OncoDaily IO

OncoDaily IO/LinkedIn

Jul 30, 2025, 17:50

New Paper Alert: Perioperative Chemoimmunotherapy In Resectable Stage II–IIIA NSCLC – OncoDaily IO

OncoDaily IO shared a post on LinkedIn:

“New Paper Alert – JAMA Network Open.

Real-world data confirms: Perioperative chemoimmunotherapy significantly improves 18-month distant metastasis-free survival (DMFS) in resectable stage II-IIIA NSCLC.

Yet in 2023, <30% of eligible patients received it.

Key Study Highlights:

N = 1,334 | Flatiron Health EHR database
DMFS:
Neoadjuvant: 80.2%
Adjuvant: 83.0%
DMFS ≥95% when ≥12 months of adjuvant immunotherapy is completed

Challenges Identified:

Underutilization in real-world settings
Suboptimal biomarker testing (<60% in neoadjuvant cohort)
Variability in treatment duration

Urgent need for:

Improved biomarker testing workflows
Greater multidisciplinary uptake

Read the full study: Desai et al, JAMA Network Open, June 2025.

Summary.“

OncoDaili IO

Aakash Desai Aaron B. Cohen Anca Marinescu cancer Catherine Keane Emily Castellanos Erin Fidyk George Ho Jonathan Bryan Karen Schwed Katherine Harrison Laurynas Kalesinskas Lung cancer NSCLC OncoDaily OncoDaily IO Oncology Qianyu Yuan Ticiana A. Leal.

IMvigor011 Trial Reports ctDNA as Predictor of Response to Adjuvant Atezolizumab in Bladder Cancer

Ruben Mesa is Starting a New Position as President of Cancer National Service Line at Advocate Health

Patrick Soon-Shiong: 30 Years and $3B Toward a Universal Cancer Fighter

Dana Dornsife: After 19 Years, Lazarex Cancer Foundation Is Shuttering Because of Lack of Funding

Matt Sherer: ASCO Supports Permanent Medicare Telehealth